
ACT Brief: APAC Trial Advantages, Learning From Setbacks, and Sunharbo Stroke Prevention Approval
11.11.2026
0:00
1:41
In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.
Weitere Episoden von „Applied Clinical Trials“



Verpasse keine Episode von “Applied Clinical Trials” und abonniere ihn in der kostenlosen GetPodcast App.








